Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Investigating the Efficacy of GON Blocks.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04017741
Recruitment Status : Recruiting
First Posted : July 12, 2019
Last Update Posted : July 23, 2019
Sponsor:
Information provided by (Responsible Party):
Barts & The London NHS Trust

Brief Summary:
Greater occipital nerve block ("GON block") is carried out extensively in the treatment of chronic migraine, but more research is required to understand the effectiveness of the procedure. It consists of a superficial injection of local anaesthetic and steroid around a nerve at the back of the head that supplies sensation to part of the scalp. This study intends to provide more detailed information on the effectiveness, safety and tolerability of GON block with local anaesthetic and steroid in patients with chronic migraine. It does this by comparing it to a dummy (placebo) procedure (a needle is inserted near the nerve, but no therapeutic substance is injected). It is a "cross-over study": all patients will receive both the GON block and the dummy procedure (not necessarily in that order), with a period in between to assess the response to the first injection. The GON block will entail an injection of 2 mls of 2% lidocaine (a local anaesthetic) and 80 mg of DepoMedrone (a steroid) through a fine needle (a total of 4 mls). The dummy procedure will consist of an injection of 4 mls of normal saline (a solution of common salt and water) through a fine needle. Patients will be followed up at various time points throughout 6 months whilst being enrolled on the study.

Condition or disease Intervention/treatment Phase
Migraine Chronic Migraine, Headache Drug: Combined Depo-Medrone and Lidocaine Drug: Sodium Chloride 0.9% Inj Phase 4

Detailed Description:

Chronic migraine is characterised by frequency of headache ≥ 15 days per month for more than 3 months. The location can be unilateral or bilateral. Usually described as pulsating in nature, it may be aggravated by, or cause avoidance of, routine activities of daily living. There can be associated light and noise sensitivity. Greater occipital nerve (GON) blockade with local anaesthetics and steroids has been used as a preventative strategy for a range of headaches including, migraine, cluster headache and hemicrania continua.

The occipital nerves have a sensory distribution in the occipital area. The greater occipital nerve derives most of its fibres from the C2 dorsal root [6]. It passes over the superior nuchal line, mid-way between the mastoid process and the occipital protuberance, just lateral to the insertion of the nuchal ligaments. The lesser occipital nerve passes lateral to the greater occipital nerve, over the nuchal ridge. Although the exact mechanism of action remains unclear, injection of steroid in the vicinity of GON nerve can have both a local effect (decreasing nociception) and a delayed central nociceptive response, possibly through an action on trigeminocervical relay

Although GON block is carried out extensively in the prophylaxis of chronic migraine, the evidence remains equivocal. In the UK, the National Institute for Clinical Excellence have yet to include GON blocks in their guidance and protocols on the treatment of both chronic headache and migraine. This randomised, single-blinded, placebo-controlled multicentre cross-over study intends to assess the efficacy, safety and tolerability of greater occipital nerve block with local anaesthetic and steroid in patients with chronic migraine with the primary objective to investigate any improvement in disability associated with chronic migraine disorder. We also intend to identify any economic outcomes associated with these injections in the management of chronic migraine.

GON block with local anaesthetic and steroid for chronic migraine and the placebo procedure will be performed in the outpatient setting. They will be carried out only by appropriately qualified members of the research team adhering to strict aseptic conditions and following standard operating protocols with regards to admission and discharge criteria in the outpatient settings.

GON block is routinely carried out in the UK and poses minimal risks to the patient. Although GON block is carried out extensively in prophylaxis of chronic migraine, the evidence remains equivocal. In the UK, the National Institute for Health and Care Excellence (NICE) have yet to include GON blocks in their guidance and protocols on the treatment of both chronic headache and migraine.

The aim of this study is to assess the efficacy, safety and tolerability of greater occipital nerve block with local anaesthetic and steroid in patients with chronic migraine of more than three months' duration.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Consented participants will be individually randomised by the Principal Investigator (PI) in a 1:1 ratio to receive either the GON block (active group) or the placebo injection (control group).
Masking: Double (Participant, Investigator)
Masking Description: This is a blinded, placebo controlled study, whereby the patient and the research team except for the injector are blinded.
Primary Purpose: Prevention
Official Title: A Phase IV Single Blind Placebo-controlled Cross Over Study to Investigate the Efficacy of Greater Occipital Nerve Block With Local Anesthetic and Steroid in Patients With Chronic Migraine
Actual Study Start Date : February 14, 2018
Estimated Primary Completion Date : July 31, 2019
Estimated Study Completion Date : December 31, 2019


Arm Intervention/treatment
Active Comparator: Active group
The active group will be administered 2 mls of 2% lidocaine and 80mg methylprednisolone.
Drug: Combined Depo-Medrone and Lidocaine

Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.

Patients who no longer receive any benefit will be crossed over to the placebo arm.

Other Names:
  • Methylprednisolone Acetate BP 40mg/mL:
  • Lidocaine Hydrochloride 2%:

Drug: Sodium Chloride 0.9% Inj
Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
Other Name: normal saline 0.9%

Placebo Comparator: Placebo group
The placebo group will be administered 4mls of 0.9% saline.
Drug: Combined Depo-Medrone and Lidocaine

Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle, the IMPs are injected at a 90 degrees angle till the bony endpoint is obtained. A combination of 2 mls of 2% lidocaine and 80mg methylprednisolone will be administered.

Patients who no longer receive any benefit will be crossed over to the placebo arm.

Other Names:
  • Methylprednisolone Acetate BP 40mg/mL:
  • Lidocaine Hydrochloride 2%:

Drug: Sodium Chloride 0.9% Inj
Patients will be randomised 1:1 to receive the active or placebo arm. The nerve is located along the superior nuchal line, where it bilaterally lies medial to the occipital artery. The scalp is prepped with alcohol and using 23G needle the 4mls of normal saline (0.9%) are injected at a 90 degrees angle till the bony endpoint is obtained. Patients who no longer receive any benefit will be crossed over to the active arm.
Other Name: normal saline 0.9%




Primary Outcome Measures :
  1. The changes in disability associated with chronic migraine disorder at baseline [ Time Frame: Baseline ]
    The average change in HIT-6 scores which measures six patient self-assessment-questions and helps distinguish the impact the effect of headache and its treatment on the patient's functional status and quality of life.

  2. The changes in baseline headache impact test scores (HIT-6) at 4 weeks [ Time Frame: 4 weeks ]
    The average change in HIT-6 scores which measures six patient self-assessment-questions and helps distinguish the impact the effect of headache and its treatment on the patient's functional status and quality of life.

  3. The changes in baseline headache impact test scores (HIT-6) at 8 weeks [ Time Frame: 8 weeks ]
    The average change in HIT-6 scores which measures six patient self-assessment-questions and helps distinguish the impact the effect of headache and its treatment on the patient's functional status and quality of life.

  4. The changes in baseline headache impact test scores (HIT-6) at 12 weeks [ Time Frame: 12 weeks ]
    The average change in HIT-6 scores which measures six patient self-assessment-questions and helps distinguish the impact the effect of headache and its treatment on the patient's functional status and quality of life.

  5. The changes in baseline headache impact test scores (HIT-6) at 16 weeks [ Time Frame: 16 weeks ]
    The average change in HIT-6 scores which measures six patient self-assessment-questions and helps distinguish the impact the effect of headache and its treatment on the patient's functional status and quality of life.

  6. The changes in baseline headache impact test scores (HIT-6) at 20 weeks [ Time Frame: 20 weeks ]
    The average change in HIT-6 scores which measures six patient self-assessment-questions and helps distinguish the impact the effect of headache and its treatment on the patient's functional status and quality of life.

  7. The changes in baseline headache impact test scores (HIT-6) at 24 weeks [ Time Frame: 24 weeks ]
    The average change in HIT-6 scores which measures six patient self-assessment-questions and helps distinguish the impact the effect of headache and its treatment on the patient's functional status and quality of life.

  8. change in quality of life relating to migraine at baseline [ Time Frame: baseline ]
    average change MSQ (Migraine Specific Quality of Life Questionnaire) to assess quality of life relating to migraine. MSQ Version 2.1 consists of 14 questions.

  9. change in quality of life relating to migraine from baseline at 4 weeks [ Time Frame: 4 weeks ]
    average change MSQ (Migraine Specific Quality of Life Questionnaire) to assess quality of life relating to migraine. MSQ Version 2.1 consists of 14 questions.

  10. change in quality of life relating to migraine from baseline at 8 weeks [ Time Frame: 8 weeks ]
    average change MSQ (Migraine Specific Quality of Life Questionnaire) to assess quality of life relating to migraine. MSQ Version 2.1 consists of 14 questions.

  11. change in quality of life relating to migraine from baseline at 12 weeks [ Time Frame: 12 weeks ]
    average change MSQ (Migraine Specific Quality of Life Questionnaire) to assess quality of life relating to migraine. MSQ Version 2.1 consists of 14 questions.

  12. change in quality of life relating to migraine from baseline at 16 weeks [ Time Frame: 16 weeks ]
    average change MSQ (Migraine Specific Quality of Life Questionnaire) to assess quality of life relating to migraine. MSQ Version 2.1 consists of 14 questions.

  13. change in quality of life relating to migraine from baseline at 20 weeks [ Time Frame: 20 weeks ]
    average change MSQ (Migraine Specific Quality of Life Questionnaire) to assess quality of life relating to migraine. MSQ Version 2.1 consists of 14 questions.

  14. change in quality of life relating to migraine from baseline at 24 weeks [ Time Frame: 24 weeks ]
    average change MSQ (Migraine Specific Quality of Life Questionnaire) to assess quality of life relating to migraine. MSQ Version 2.1 consists of 14 questions.

  15. change in health related quality of life associated with chronic migraine disorder at baseline [ Time Frame: baseline ]
    The changes reported in the short form survey with 12 questions (SF-12), comprised of two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life.

  16. change in health related quality of life associated with chronic migraine disorder from baseline at 4 weeks [ Time Frame: 4 weeks ]
    The changes reported in the short form survey with 12 questions (SF-12), comprised of two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life.

  17. change in health related quality of life associated with chronic migraine disorder from baseline at 8 weeks [ Time Frame: 8 weeks ]
    The changes reported in the short form survey with 12 questions (SF-12), comprised of two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life.

  18. change in health related quality of life associated with chronic migraine disorder from baseline at 12 weeks [ Time Frame: 12 weeks ]
    The changes reported in the short form survey with 12 questions (SF-12), comprised of two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life.

  19. change in health related quality of life associated with chronic migraine disorder from baseline at 16 weeks [ Time Frame: 16 weeks ]
    The changes reported in the short form survey with 12 questions (SF-12), comprised of two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life.

  20. change in health related quality of life associated with chronic migraine disorder from baseline at 20 weeks [ Time Frame: 20 weeks ]
    The changes reported in the short form survey with 12 questions (SF-12), comprised of two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life.

  21. change in health related quality of life associated with chronic migraine disorder from baseline at 24 weeks [ Time Frame: 24 weeks ]
    The changes reported in the short form survey with 12 questions (SF-12), comprised of two scales that provide glimpses into mental and physical functioning and overall health-related-quality of life.


Secondary Outcome Measures :
  1. Change in Headache frequency & Severity at baseline [ Time Frame: baseline ]
    changes in Frequency and severity as scored in the HIT-6 questionnaire. Total scores can range between 36-78. Scores higher than 60 can indicate more greater impact on patient life.

  2. Change from baseline Headache frequency & Severity at 4 weeks [ Time Frame: 4 weeks ]
    changes in Frequency and severity as scored in the HIT-6 questionnaire when compared to baseline. Total scores can range between 36-78. Scores higher than 60 can indicate more greater impact on patient life.

  3. Change from baseline Headache frequency & Severity at 8 weeks [ Time Frame: 8 weeks ]
    changes in Frequency and severity as scored in the HIT-6 questionnaire when compared to baseline. Total scores can range between 36-78. Scores higher than 60 can indicate more greater impact on patient life.

  4. Change from baseline Headache frequency & Severity at 12 weeks [ Time Frame: 12 weeks ]
    changes in Frequency and severity as scored in the HIT-6 questionnaire when compared to baseline. Total scores can range between 36-78. Scores higher than 60 can indicate more greater impact on patient life.

  5. Change from baseline Headache frequency & Severity at 16 weeks [ Time Frame: 16 weeks ]
    changes in Frequency and severity as scored in the HIT-6 questionnaire. Total scores can range between 36-78. Scores higher than 60 can indicate more greater impact on patient life.

  6. Change in Headache frequency & Severity at 20 weeks [ Time Frame: 20 weeks ]
    changes in Frequency and severity as scored in the HIT-6 questionnaire when compared to baseline.Total scores can range between 36-78. Scores higher than 60 can indicate more greater impact on patient life.

  7. Change from baseline Headache frequency & Severity at 24 weeks [ Time Frame: 24 weeks ]
    changes in Frequency and severity as scored in the HIT-6 questionnaire. Total scores can range between 36-78. Scores higher than 60 can indicate more greater impact on patient life.

  8. Change in anxiety and depression levels at baseline [ Time Frame: baseline ]
    Change in Hospital Anxiety and Depression Scores (HADS) questionnaire Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. The higher the score, the more impact the headache has on the patient's life.

  9. Change from baseline anxiety and depression levels at 4 weeks [ Time Frame: 4 weeks ]
    Change in Hospital Anxiety and Depression Scores (HADS) questionnaire when compared to baseline. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. The higher the score, the more impact the headache has on the patient's life.

  10. Change from baseline anxiety and depression levels at 8 weeks [ Time Frame: 8 weeks ]
    Change in Hospital Anxiety and Depression Scores (HADS) questionnaire when compared to baseline

  11. Change from baseline anxiety and depression levels at 12 weeks [ Time Frame: 12 weeks ]
    Change in Hospital Anxiety and Depression Scores (HADS) questionnaire when compared to baseline. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. The higher the score, the more impact the headache has on the patient's life.

  12. Change from baseline anxiety and depression levels at 16 weeks [ Time Frame: 16 weeks ]
    Change in Hospital Anxiety and Depression Scores (HADS) questionnaire when compared to baseline. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. The higher the score, the more impact the headache has on the patient's life.

  13. Change from baseline anxiety and depression levels at 20 weeks [ Time Frame: 20 weeks ]
    Change in Hospital Anxiety and Depression Scores (HADS) questionnaire when compared to baseline. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. The higher the score, the more impact the headache has on the patient's life.

  14. Change from baseline anxiety and depression levels at 24 weeks [ Time Frame: 24 weeks ]
    Change in Hospital Anxiety and Depression Scores (HADS) questionnaire when compared to baseline. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. The higher the score, the more impact the headache has on the patient's life.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged over the age of 18 who are able to provide a written consent
  • Ability to read and write English, due to questionnaire use in study
  • Diagnosis of chronic migraine with or without acute relief medication overuse (ICHD-III codes 1.3 and 8.2); as confirmed by diary documentation (headache on 15 or more days a month for at least 3 months)

Exclusion Criteria:

  • Patient refusal
  • Participation in any trial of any investigational products or interventional research project within the previous eight weeks to enrolment
  • Patients unable to commit to the six-month study duration (PI judgment)
  • Any known contraindication(s) to the IMPs as described by the manufacturer's Summary of Product Characteristics (SmPCs)
  • Patients with a history of substance abuse
  • Pregnant or breastfeeding patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04017741


Contacts
Layout table for location contacts
Contact: Vivek Mehta + 44 203 765 8878 vivek.mehta@bartshealth.nhs.uk

Locations
Layout table for location information
United Kingdom
Barts Health NHS Trust Recruiting
London, United Kingdom, EC1A 4NP
Contact: Vivek Mehta       vivek.mehta@nhs.net   
Principal Investigator: Anish Bahra         
Sub-Investigator: Alia Ahmad         
Sponsors and Collaborators
Barts & The London NHS Trust
Investigators
Layout table for investigator information
Principal Investigator: Anish Bahra University College London Hospital

Layout table for additonal information
Responsible Party: Barts & The London NHS Trust
ClinicalTrials.gov Identifier: NCT04017741     History of Changes
Other Study ID Numbers: 009665 BLT
First Posted: July 12, 2019    Key Record Dates
Last Update Posted: July 23, 2019
Last Verified: April 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by Barts & The London NHS Trust:
Chronic migraine, GON blocks

Additional relevant MeSH terms:
Layout table for MeSH terms
Migraine Disorders
Headache
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Pain
Neurologic Manifestations
Signs and Symptoms
Lidocaine
Methylprednisolone
Methylprednisolone Acetate
Methylprednisolone Hemisuccinate
Prednisolone
Prednisolone acetate
Prednisolone hemisuccinate
Prednisolone phosphate
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents